A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

ConditionsHead and Neck Squamous Cell Carcinoma Soft Tissue Sarcoma Adult Triple Negative Breast Cancer

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorPure Biologics S.A.

About this trial

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

PBA-0111

Treatment groups

12 Participants

are divided into 1 treatment group

Sponsors and collaborators

Pure Biologics S.A.

Lead sponsor

Source ClinicalTrials.gov